Legislative MemoContact: |
|||||||||||||||||||
|
|||||||||||||||||||
|
Current federal Food and Drug Administration regulations already require all over the counter drug labels to contain information about product ingredients and safe use. The FDA has an extensive clinical review process in place that supports product labeling. Congress has recognized that state and local labeling requirements that differ from federal requirements would create contradictory directions and warnings, confuse consumers and undermine public confidence in the federal government’s regulatory system. The majority of manufacturers produce and distribute products on a regional, if not a national basis. Due to the interstate nature of this process, state-specific labeling laws would create a significant impediment to interstate commerce. The Business Council opposes the creation of a state-specific labeling law, and respectfully urges the rejection of A.9281-A / S.6281-C.
|
|||||||||||||||||||